Related Experiment Video
Updated: Mar 3, 2026
06:54
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
3.4K
Cerebrolysin for acute ischaemic stroke
Liliya Eugenevna Ziganshina1, Tatyana Abakumova2, Ludivine Vernay3
1Research & Education Centre for Evidence-Based Medicine Cochrane Russia, Kazan (Volga region) Federal University, 18 Kremlevskaya Street, 420008, 14-15 Malaya Krasnaya Street, 420015, Kazan, Tatarstan, Russian Federation.
The Cochrane Database of Systematic Reviews
|April 22, 2017
Summary
This review found no clinical benefits of cerebrolysin for acute ischemic stroke treatment. While overall serious adverse events (SAEs) did not differ, non-fatal SAEs increased with cerebrolysin use.
Area of Science:
- Neurology
- Pharmacology
Background:
- Cerebrolysin, a peptide mixture from pig brains, is used for acute ischemic stroke in several countries.
- It is believed to possess neuroprotective and neurotrophic properties.
Purpose of the Study:
- To evaluate the efficacy and safety of cerebrolysin in treating acute ischemic stroke.
Main Methods:
- A systematic review of randomized controlled trials (RCTs) comparing cerebrolysin with placebo or no treatment.
- Searches included multiple databases up to May 2016, reference lists, ongoing trials, and manufacturer contact.
- Six RCTs with 1501 participants met the inclusion criteria; risk of bias was assessed.
Main Results:
- No trials reported on poor functional outcomes or early death.
- All-cause mortality showed no significant difference between cerebrolysin and placebo groups (RR 0.91, 95% CI 0.61 to 1.35).
- A statistically significant increase in non-fatal serious adverse events (SAEs) was observed with cerebrolysin (RR 2.47, 95% CI 1.09 to 5.58).
Conclusions:
- Current evidence does not support the clinical benefits of cerebrolysin for acute ischemic stroke.
- Moderate-quality evidence indicates an increased risk of non-fatal SAEs with cerebrolysin treatment.
